FARMAPHAR

Active

Private limited companyfounded 2015active for 11 yearsClemenceaustraat 43, 2860 Sint-Katelijne-Waver, BelgiumKBO/BCE: BE 0607.999.166

From the official registers: KBO 10 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

FARMAPHAR has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €46,889 and a net result of €96,414. Equity is growing by about 24% per year across the filed financial years. Its solvency ranks better than 18% of 12,737 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).

Risk analysisFollow Report Compare

FARMAPHARActiveChecked score 83/100

Risk analysis Report Compare

Official details

KBO

Status: Active since 25-03-2015 Normal situation
Legal form: Private limited company
Registered office: Clemenceaustraat 43, 2860 Sint-Katelijne-Waver
Activity: Retail sale of pharmaceutical products NACE 47730
Establishment unit: 2.241.509.652 2860 Sint-Katelijne-Waver, since 25-03-2015
Financial year end: 31 December
Peppol: Reachable since 24-11-2023

Company details

Who decides

Board

Hooijmaaijer JohannaDirector · since 25-03-2015

Board & ownership

How it is doing

83 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.4%

Annual accounts 2025

Gross margin: €249,436; ▲ 38.1%
Turnover: ≈ €1.2m; estimated
Profit: €96,414; ▲ 102%
Equity: €46,889; ▼ 61.5%
Total assets: €634,998; ▼ 30.2%
Staff: 1 FTE; ▲ 42.9%

2025 accounts 28 days early

Filed on 03-07-2026at the National Bank

Financials

Why 83raises riskEquity €46,889 (7.4% of total assets)Sector: Retail trade (NACE 47)lowers riskFounded in 2015Figures for financial year 2025 (filed 03-07-2026)Show the evidence

Checked score

Score 2025

83 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 42% of its sector peers (NACE 47, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Average

Solvency 32-6

equity 7.4% of total assets

Liquidity 50+7

short-term debt 92.2% · cash 45.1%

Profitability 88+42

return on assets 15.2%

Bankruptcy probability, 12 months

0.4% Very low

0%0.5%1.5%4%10%≥ 25%

About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,270 companies, NACE 47, micro)

Last 24 months 11-2024: 0.1%lowest value 12-2024: 0.1%● unchanged vs 11-2024lowest value 01-2025: 0.1%● unchanged vs 12-2024lowest value 02-2025: 0.1%● unchanged vs 01-2025lowest value 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.2%▲ +0.1 percentage points vs 06-2025 08-2025: 0.4%▲ +0.2 percentage points vs 07-2025 09-2025: 0.4%● unchanged vs 08-2025 10-2025: 0.4%● unchanged vs 09-2025 11-2025: 0.4%● unchanged vs 10-2025 12-2025: 0.4%● unchanged vs 11-2025 01-2026: 0.4%● unchanged vs 12-2025 02-2026: 0.4%● unchanged vs 01-2026 03-2026: 0.4%● unchanged vs 02-2026 04-2026: 0.4%● unchanged vs 03-2026 05-2026: 0.4%● unchanged vs 04-2026 06-2026: 0.4%● unchanged vs 05-2026 07-2026: 0.5%▲ +0.1 percentage points vs 06-2026highest value 08-2026: 0.4%▼ -0.1 percentage points vs 07-2026 09-2026: 0.4%● unchanged vs 08-2026 10-2026: 0.4%● unchanged vs 09-2026

Credit of up to €3,500 on 30-day terms is acceptable

Liquidity insufficient (current ratio 0.83, compared with 0.98 in 2024, below 1; short-term debt: 92.2% and cash: 45.1% of total assets), and 92.6% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 24% on solvency, 52% on liquidity, 83% on profitability and 9% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises riskneutral

Equity €46,889 (7.4% of total assets)

NBB · annual accounts

Sector: Retail trade (NACE 47)

KBO

Founded in 2015

Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.

KBO

Figures for financial year 2025 (filed 03-07-2026)

NBB · annual accounts

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 18% of 12737 sector peers (2025).

NBB · sector comparison

Position among 12737 sector peers

Solvency

better than 18%

← weakest strongest →

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

28 days early

2024

14 days early

2023

23 days early

2022

30 days late

2021

3 days late

2020

4 days early

2019

1 day early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 5 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 17 July (4 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

01-11-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

Key points

Caution: Equity fell in 2025from €121,889 to €46,889 ▼ 61.5% View
Caution: Among the weakest 19% on solvencysector median 36.6% · 12,737 companies 7.4% View
Positive: 8 profitable years in a rowprofit 2025: €96,414 8 years View

Documents

Key facts about FARMAPHAR

What is the company number of FARMAPHAR?: 0607.999.166. In Belgium the VAT number is the company number with BE in front: BE 0607.999.166.
Where is FARMAPHAR based?: The registered office is at Clemenceaustraat 43, 2860 Sint-Katelijne-Waver.Company details
What does FARMAPHAR do?: According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of FARMAPHAR?: Private limited company (BV).
When was FARMAPHAR founded?: On 25-03-2015.
Is FARMAPHAR still active?: Yes, FARMAPHAR is an active enterprise in the KBO register.
How many employees does FARMAPHAR have?: On average 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of FARMAPHAR?: ≈ €1.2m in financial year 2025. Estimated from the gross margin of €249,436: probably between €790,000 and €2.3m, based on 51 comparable companies, NACE 477.
Is FARMAPHAR profitable?: In financial year 2025, FARMAPHAR made a profit of €96,414.
Where can I find the annual accounts of FARMAPHAR?: FARMAPHAR filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of FARMAPHAR due?: By 31-07-2027, for financial year 2026.Timeline

Companies related to FARMAPHAR

Comparable companies

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

Overview